ライフサイエンスコーパス: severe combined immunodeficient

1 In severe combined immunodeficient beige mouse models of MC

2 an CD19(+) tumors in immunocompromised SCID (severe combined immunodeficient)-Beige mice.

3 tacrolimus, Bonferroni's P<0.001) and in the severe combined immunodeficient-beige mice (117+/-18 in

4 BALB/c mice or severe combined immunodeficient-beige mice were treated

5 lones, grow in soft agar, and form tumors in severe combined immunodeficient-beige mice.

6 fused W6/32 Fab'2 antibody to human HLA into severe combined immunodeficient/beige mice that had been

7 To address this we used nonobese diabetic-severe combined immunodeficient-beta(2) microglobulin kn

8 ion of ospA mRNA was found in tissues of C3H-severe combined immunodeficient (C3H-scid) mice, but not

9 Human fetal lung tissue was implanted into severe combined immunodeficient (CB17-scid) mice and ino

10 l evidence that in a recombination inducible severe combined immunodeficient cell line poly(ADP-ribos

11 Humanized nonobese diabetic severe combined immunodeficient common gamma chain-defic

12 islets under the kidney capsule in diabetic severe combined immunodeficient (d-SCID) mice.

13 s to restore euglycemia in nonobese diabetic/severe combined immunodeficient diabetic recipients was

14 the recurrence of autoimmune diabetes in NOD/severe combined immunodeficient disease (SCID) islet iso

15 al vein of either C57BL/6 (DNA-PKcs(+/+)) or severe combined immunodeficient (DNA-PKcs(-/-)) mice.

16 Nonobese diabetic severe combined immunodeficient gammac(-/-) (NSG) mice r

17 self-antigen-specific CTLs in vitro and in a severe combined immunodeficient-hu mouse model.

18 In contrast to nonobese diabetic severe combined immunodeficient Il2rg(-/-) (NSG) mice, h

19 f immunocompetent limited flora (I-LF) mice, severe combined immunodeficient limited flora (SCID-LF)

20 antation of these cells in nonobese diabetic-severe combined immunodeficient mice (a) generated xenog

21 fts in three genetically isolated strains of severe combined immunodeficient mice (C.B-17, C57BL/6J,

22 uction of the human HGF ligand in transgenic severe combined immunodeficient mice (hHGF(tg)-SCID mice

23 Groups 1 to 4 of severe combined immunodeficient mice (n = 5-7 per group)

24 weeks old abortuses were xenografted s.c. to severe combined immunodeficient mice (n = 52).

25 onset of diabetes in young nonobese diabetic-severe combined immunodeficient mice (NOD.scid).

26 mum tolerated dose of 2L-Rap-hLL1-gamma4P in severe combined immunodeficient mice (SCID) or BALB/c mi

27 ntitumor effects were markedly diminished in severe combined immunodeficient mice and (b) CD8+ T cell

28 Human fetal bones were implanted in severe combined immunodeficient mice and after 4 weeks,

29 aneously implanted into the left shoulder of severe combined immunodeficient mice and evaluated.

30 nted tumors when transplanted into syngeneic severe combined immunodeficient mice and normal mice.

31 MDMs were injected into the basal ganglia of severe combined immunodeficient mice and then Li was adm

32 e studied the effects of THMAM-MD in vivo in severe combined immunodeficient mice bearing HT-29 colon

33 In nonobese diabetic/severe combined immunodeficient mice bearing human EBV l

34 We found that pretreatment of severe combined immunodeficient mice bearing human intes

35 ncer and significantly prolonged survival of severe combined immunodeficient mice bearing LAPC-4 xeno

36 activity of 8H9(scFv)-PE38 was evaluated in severe combined immunodeficient mice bearing MCF-7 breas

37 In the current study, severe combined immunodeficient mice bearing s.c. tumors

38 In severe combined immunodeficient mice bearing SKOV3 tumor

39 PET/CT small-animal imaging was performed in severe combined immunodeficient mice bearing solid and d

40 Severe combined immunodeficient mice bearing U87MG xenog

41 e drug combination decreased tumor volume in severe combined immunodeficient mice by approximately 60

42 growth and the gain in mean tumor volume in severe combined immunodeficient mice compared with vehic

43 nd engraft immunodeficient nonobese diabetes/severe combined immunodeficient mice during both primary

44 cific neutralizing anti-CXCL12 antibodies to severe combined immunodeficient mice expressing human no

45 on of late-passage H-Ras-expressing cells in severe combined immunodeficient mice formed carcinomas w

46 eplication in nontumor tissues and protected severe combined immunodeficient mice from developing let

47 was used in vivo to treat nonobese diabetic/severe combined immunodeficient mice given injections of

48 Severe combined immunodeficient mice harboring U87 xenog

49 he marrow space of the bone implanted in the severe combined immunodeficient mice implanted with feta

50 0530 profoundly inhibits tumor metastasis in severe combined immunodeficient mice implanted with GRP-

51 opic HIV-1(JR-CSF) isolate (JR-CSF mice) and severe combined immunodeficient mice implanted with huma

52 An in vivo efficacy trial with severe combined immunodeficient mice implanted with subc

53 ndent growth in vitro and tumor formation in severe combined immunodeficient mice in vivo.

54 implanted as xenografts in nonobese diabetic/severe combined immunodeficient mice in vivo.

55 CDV) and octadecyloxyethyl-CVD (ODE-CDV)--in severe combined immunodeficient mice in which either hum

56 5(+) T cells to infected macrophage-depleted severe combined immunodeficient mice induced CNS demyeli

57 ionship between phospho-AKT and FAS in vivo, severe combined immunodeficient mice injected intraperit

58 meliorated adoptively transferred ileitis in severe combined immunodeficient mice injected with CD4 +

59 Nonobese diabetic severe combined immunodeficient mice lacking the cytokin

60 dies, BMSCs and ECs were cotransplanted into severe combined immunodeficient mice on biodegradable po

61 t study, we induced EAE in T-cell-deficient, severe combined immunodeficient mice or in immunocompete

62 t VEGF111 addition before transplantation to severe combined immunodeficient mice ovaries.

63 macrophages (MDMs) into the basal ganglia of severe combined immunodeficient mice recapitulates histo

64 th a targeted deletion of the T-bet gene and severe combined immunodeficient mice receiving CD4+ cell

65 er growth was evaluated in hu-PBL-SCID mice (severe combined immunodeficient mice reconstituted with

66 Severe combined immunodeficient mice remained persistent

67 uman ovarian tumor cells into the ovaries of severe combined immunodeficient mice resulted in periton

68 racranial implantation of human gliomas into severe combined immunodeficient mice showed a marked red

69 The standard adoptive transfer study in NOD-severe combined immunodeficient mice showed that periphe

70 Severe combined immunodeficient mice that received purge

71 following immunization of nonobese diabetic-severe combined immunodeficient mice that were repopulat

72 R, and DeltaB-Raf:ER cells to form tumors in severe combined immunodeficient mice was compared.

73 Intratibial tumor injection in severe combined immunodeficient mice was used to simulat

74 cells harvested from carcinoma formation in severe combined immunodeficient mice were designated caM

75 Female severe combined immunodeficient mice were fed a low-fat/

76 Severe combined immunodeficient mice were given injectio

77 When severe combined immunodeficient mice were injected with

78 Severe combined immunodeficient mice were reconstituted

79 Severe combined immunodeficient mice were reconstituted

80 tin-expressing tumors grown as xenografts in severe combined immunodeficient mice were responsive to

81 cTVT fragments grown in severe combined immunodeficient mice were successfully i

82 M21 (human melanoma)-bearing severe combined immunodeficient mice were used for biodi

83 ive, Fc-dependent, passive immunity, even in severe combined immunodeficient mice with an established

84 inst subcutaneous B-cell tumor xenografts in severe combined immunodeficient mice with comparable or

85 KLMS-1 and rhabdomyosarcoma RD xenografts in severe combined immunodeficient mice with DC101 resulted

86 HCV-infected urokinase plasminogen activator-severe combined immunodeficient mice with livers repopul

87 Furthermore, Kp-10 inhibits tumor growth in severe combined immunodeficient mice xenografted with hu

88 Severe combined immunodeficient mice xenografted with M2

89 volume, rate of metastasis, and mortality of severe combined immunodeficient mice xenografted with PC

90 model originating from footpad injection in severe combined immunodeficient mice, 95% of the resulti

91 ere injected directly into the peritoneum of severe combined immunodeficient mice, and in a syngeneic

92 neither resulted in weight loss nor death in severe combined immunodeficient mice, and pock lesions w

93 the growth of TPras transgenic melanomas in severe combined immunodeficient mice, blocked invasive b

94 model established by tail vein injection in severe combined immunodeficient mice, clonality of lung

95 In severe combined immunodeficient mice, Ebp1 overexpressio

96 sgene expression was substantially higher in severe combined immunodeficient mice, indicating that in

97 as far less efficacious in immunocompromised severe combined immunodeficient mice, indicating the req

98 The severe combined immunodeficient mice, on the other hand,

99 ally injected into the basal ganglia of CB17 severe combined immunodeficient mice, received daily int

100 When Cyno-1 cells were injected into severe combined immunodeficient mice, teratomas with der

101 In severe combined immunodeficient mice, the antitumor effi

102 When injected into the mammary fat pads of severe combined immunodeficient mice, the tumors formed

103 Additionally, in in vivo studies in severe combined immunodeficient mice, there was signific

104 marrow of human bones that were implanted in severe combined immunodeficient mice, tumors formed by c

105 Finally, using an angiogenesis assay in severe combined immunodeficient mice, we demonstrate tha

106 lls, bone marrow chimeras, and reconstituted severe combined immunodeficient mice, we identify the pr

107 human stem cell-engrafted nonobese diabetic/severe combined immunodeficient mice, where 24% of the h

108 ation of SKOV3ip1 cells in nonobese diabetic/severe combined immunodeficient mice, with increased pho

109 In severe combined immunodeficient mice, xenograft tumors e

110 tumor formation and inhibited metastasis in severe combined immunodeficient mice.

111 sicles in a model of glycerol-induced AKI in severe combined immunodeficient mice.

112 nt growth in soft agar, and tumorigenesis in severe combined immunodeficient mice.

113 an carcinomas implanted in immunocompromised severe combined immunodeficient mice.

114 ity in prostate cancer tumors implanted into severe combined immunodeficient mice.

115 ompetitive repopulation of nonobese diabetic/severe combined immunodeficient mice.

116 -reperfusion-injured adult nonobese diabetic-severe combined immunodeficient mice.

117 homa cells were intravitreally injected into severe combined immunodeficient mice.

118 ction on PLC/PRF/5 human tumor xenografts in severe combined immunodeficient mice.

119 in soft agar as well as s.c. tumor growth in severe combined immunodeficient mice.

120 on, led to the formation of larger tumors in severe combined immunodeficient mice.

121 mor cell growth and invasion in vitro and in severe combined immunodeficient mice.

122 and these cells were grown as xenografts in severe combined immunodeficient mice.

123 f resistant multiple myeloma tumors (MM1) in severe combined immunodeficient mice.

124 tibody targeted to HER2-expressing tumors in severe combined immunodeficient mice.

125 variant of SN12C) tumors grown in kidneys of severe combined immunodeficient mice.

126 gnals as shown in chimeric nonobese diabetic/severe combined immunodeficient mice.

127 LAPC-4 cells were injected into male severe combined immunodeficient mice.

128 antation into the mammary fat pads of female severe combined immunodeficient mice.

129 ndrogen-independent DU145 prostate cancer in severe combined immunodeficient mice.

130 MET-1 leukemic cells into nonobese diabetic/severe combined immunodeficient mice.

131 s when these cells were inoculated s.c. into severe combined immunodeficient mice.

132 into cardiomyocytes in the injured hearts of severe combined immunodeficient mice.

133 ) from an ATL patient into nonobese diabetic/severe combined immunodeficient mice.

134 colonization potential after injection into severe combined immunodeficient mice.

135 by a neutralizing antibody to human CXCR4 in severe combined immunodeficient mice.

136 econstitute the marrow of non-obese diabetic severe combined immunodeficient mice.

137 ited lung colonization of the tumor cells in severe combined immunodeficient mice.

138 n into the left subrenal capsule of diabetic severe combined immunodeficient mice.

139 ression was studied in nonobese diabetic and severe combined immunodeficient mice.

140 we implanted human-derived glioma cells into severe combined immunodeficient mice.

141 ling of human coronary artery transplants in severe combined immunodeficient mice.

142 nd also in tumors in prostate-tumor-bearing, severe combined immunodeficient mice.

143 or supplemented (GFS) matrigel into diabetic severe combined immunodeficient mice.

144 reotactically injected into the subcortex of severe combined immunodeficient mice.

145 tail vein of MDA-MB-231 tumor-bearing female severe combined immunodeficient mice.

146 sed invasiveness of MCF10.DCIS xenografts in severe combined immunodeficient mice.

147 ng highly invasive HCC in nonobese diabetic, severe combined immunodeficient mice.

148 raftment of these cells in nonobese diabetic/severe combined immunodeficient mice.

149 d not express uPAR formed palpable tumors in severe combined immunodeficient mice; however, metastase

150 asion assays, and/or injected into flanks of severe combined immunodeficient mice; xenograft tumor gr

151 owth of malignant mesothelioma xenografts in severe-combined immunodeficient mice and extended host s

152 This report uses severe-combined immunodeficient mice given injections of

153 cells were injected intratibially in C3H and severe-combined immunodeficient mice.

154 C1 was seen toward H460 tumor xenografts in severe-combined immunodeficient mice.

155 line (EGI-1) after xenotransplantation into severe-combined-immunodeficient mice, (3) expression of

156 6Mre11(ATLD1/ATLD1) and C57BL/6(Prkdc/SCID) (severe combined immunodeficient) mice exposed to low-dos

157 ation in soft agar, tumor formation in SCID (severe combined immunodeficient) mice, and adhesion.

158 eotide-binding oligomerization domain)/SCID (severe combined immunodeficient) mice.

159 edium before transfer to Prkdc(scid)-mutant (severe combined immunodeficient) mice.

160 an peripheral blood leukocytes (hu PBL-SCID [Severe Combined Immunodeficient] mice) to test the hypot

161 A human/severe combined immunodeficient mouse chimeric model was

162 prevent progression of established CaP in a severe combined immunodeficient mouse implanted with fet

163 f normal islets in a streptozotocin-diabetic severe combined immunodeficient mouse marginal islet mas

164 The chimeric nonobese diabetic severe combined immunodeficient mouse model may be usefu

165 A severe combined immunodeficient mouse model of extravasa

166 In a severe combined immunodeficient mouse model of human NSC

167 Finally, using a humanized severe combined immunodeficient mouse model of lymphocyt

168 In a severe combined immunodeficient mouse model, PDGF DD exp

169 ithout affecting primary tumorigenicity in a severe combined immunodeficient mouse model.

170 development in a humanized nonobese diabetic-severe combined immunodeficient mouse model.

171 at our in vitro results can be extended to a severe combined immunodeficient mouse model.

172 S.c. xenograft assays were carried out in a severe combined immunodeficient mouse model.

173 cells, using a xenogeneic nonobese diabetic/severe combined immunodeficient mouse model.

174 inant hepatic failure in a nonobese diabetic severe combined immunodeficient mouse model.

175 one B (dEpoB) in xenograft nonobese diabetic/severe combined immunodeficient mouse models with subcut

176 eutic treatments using both cell culture and severe combined immunodeficient mouse models.

177 ound to inhibit pancreatic tumor growth in a severe combined immunodeficient mouse xenograft model.

178 c. human GD2-positive melanoma growth in the severe combined immunodeficient mouse xenograft model.

179 These investigations in a nonobese diabetic severe combined immunodeficient mouse-human neural cell

180 activation of ERK even when passed through a severe combined immunodeficient mouse.

181 dicates that the NOD/SCID (nonobese diabetic/severe combined immunodeficient) mouse model can be a va

182 ta-glucuronidase-deficient nonobese diabetic/severe combined immunodeficient/mucopolysaccharidosis ty

183 geneic graft-versus-host disease (X-GVHD) in severe combined immunodeficient murine recipients of hum

184 bet knockout (KO) mutants, or congenic SCID (severe, combined immunodeficient) mutants were given liv

185 BD islets transplanted to non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice efficien

186 arian carcinoma growth in non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice.

187 atocytes when infused into nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice.

188 marrow of immunodeficient nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice.

189 In non-obese diabetic-severe combined immunodeficient (NOD-SCID) recipients, w

190 population with use of the nonobese diabetic/severe combined immunodeficient (NOD/SCID) and NOD/SCID

191 ngraftment of AML cells in nonobese diabetic/severe combined immunodeficient (NOD/SCID) animals, and

192 The nonobese diabetic/severe combined immunodeficient (NOD/SCID) assay is the

193 ibialis anterior muscle of nonobese diabetic-severe combined immunodeficient (NOD/SCID) beta 2m(-/-)

194 higher tumor incidence in nonobese diabetic/severe combined immunodeficient (NOD/SCID) Ilgamma2(null

195 Nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice accept h

196 selected for passage into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice and mini

197 is trial transplanted into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice resulted

198 ns in the liver and gut of nonobese diabetic-severe combined immunodeficient (NOD/SCID) mice that und

199 gate the in vivo efficacy, nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice were xen

200 ultiple ALL cell lines and nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice xenograf

201 the retroorbital plexus of nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, allowed

202 IM CD34(+) cells engrafted nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, demonst

203 ncreased tumorigenicity in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, possibl

204 xenografts established in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, were di

205 f leukemia and survival in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice.

206 and primary ALL samples in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice.

207 n the peritoneal cavity of nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice.

208 marrow and the spleens of nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice.

209 Here we report that a new nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse line ha

210 er, when injected into the nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse prostat

211 We examined whether the nonobese diabetic/severe combined immunodeficient (NOD/scid) mouse, which

212 A nonobese diabetic/severe combined immunodeficient (NOD/SCID) murine xenogr

213 ll as stem cells using the nonobese diabetic/severe combined immunodeficient (NOD/SCID) xenograft mod

214 e was backcrossed onto the nonobese diabetic/severe combined immunodeficient (NOD/SCID) xenotransplan

215 Stem cell engraftment into nonobese diabetic-severe combined immunodeficient (NOD/SCID)/beta2m-/- mic

216 (+) B-cell malignancies in nonobese diabetic/severe combined immunodeficient (NOD/SCID)/gamma(c)(null

217 regression was blocked in nonobese diabetic/severe combined immunodeficient (NOD/SCID-gamma) mice, w

218 e therefore developed an in vivo MM model in severe combined immunodeficient/nonobese diabetic mice i

219 rsus FasL(-/-) mouse liver CD8(+) T cells to severe combined immunodeficient or RAG1(-/-) recipient m

220 mis, a nuclease mutated in a subset of human severe combined immunodeficient patients.

221 Immune competent, severe combined immunodeficient, RAG1-deficient, and gre

222 nfected donors expanded in reovirus-infected severe combined immunodeficient recipient mice and media

223 il also improved transduction in human SCID (severe combined immunodeficient) repopulating cell (SRC)

224 In severe combined immunodeficient (SCID) beige mouse model

225 Introduction of BCR-ABL into Arf-null severe combined immunodeficient (SCID) bone marrow proge

226 or its ability to protect wild-type (WT) and severe combined immunodeficient (SCID) C.B-17 mice again

227 uated envelope SU cloned sequences from five severe combined immunodeficient (SCID) foals infected wi

228 raacetic acid (DOTA)-RGD in 20 tumor-bearing severe combined immunodeficient (SCID) mice after a bolu

229 Similarly, VPA protects severe combined immunodeficient (SCID) mice against the

230 titumor effects of MEDI-575 in tumor-bearing severe combined immunodeficient (SCID) mice and in genet

231 xpressed in autoimmune target tissues of NOD/severe combined immunodeficient (scid) mice and of autoi

232 in the brain's extracellular space of C.B.17 severe combined immunodeficient (scid) mice and tumor ce

233 antibody significantly prolonged survival of severe combined immunodeficient (SCID) mice bearing CD70

234 f B-B4-DM1 in 3 human MM models in mice: (1) severe combined immunodeficient (SCID) mice bearing subc

235 e tissues (5-8), two studies have shown that severe combined immunodeficient (SCID) mice can be infec

236 Severe combined immunodeficient (SCID) mice carry a germ

237 iver homogenates after 24 serial passages in severe combined immunodeficient (SCID) mice caused sever

238 ted in urokinase plasminogen activator (uPA)/severe combined immunodeficient (SCID) mice engrafted wi

239 Once the treatment was discontinued, severe combined immunodeficient (SCID) mice had progress

240 -dependent protein kinase (DNA-PK)-defective severe combined immunodeficient (SCID) mice have a great

241 be here a novel in vivo model of human WM in severe combined immunodeficient (SCID) mice implanted wi

242 In severe combined immunodeficient (SCID) mice injected wit

243 splantation of purified HSCs into a panel of severe combined immunodeficient (SCID) mice leads to a r

244 and their splenocytes were transferred into severe combined immunodeficient (SCID) mice to induce IT

245 man dorsal root ganglion (DRG) xenografts in severe combined immunodeficient (SCID) mice to investiga

246 Groups of severe combined immunodeficient (SCID) mice were first i

247 Severe combined immunodeficient (SCID) mice were infecte

248 WT) mice were subjected to DNFB-induced CHS, severe combined immunodeficient (SCID) mice were injecte

249 nificantly extends survival of 697 xenograft severe combined immunodeficient (SCID) mice without disc

250 e was tested for its metastatic potential in severe combined immunodeficient (SCID) mice, by i.v. inj

251 When coinjected with human MM cells into severe combined immunodeficient (SCID) mice, green fluor

252 When implanted subcutaneously in severe combined immunodeficient (SCID) mice, MDA-PCa-118

253 AML cells in vivo in nonobese diabetic (NOD)-severe combined immunodeficient (SCID) mice, suggesting

254 After transplantation into severe combined immunodeficient (SCID) mice, the differe

255 When implanted into severe combined immunodeficient (SCID) mice, the growth

256 ith the cDNA for heparanase are implanted in severe combined immunodeficient (SCID) mice, the resulti

257 or importantly when grown subcutaneously in severe combined immunodeficient (SCID) mice.

258 d prevented the s.c. growth of PC-3 cells in severe combined immunodeficient (SCID) mice.

259 o initiate tumors in nude and hypersensitive severe combined immunodeficient (SCID) mice.

260 nocompetent mice or T-cell-deficient mice to severe combined immunodeficient (SCID) mice.

261 or after coinjection of PA in tumor-bearing severe combined immunodeficient (SCID) mice.

262 cessfully immunized BALB/c mice to syngeneic severe combined immunodeficient (SCID) mice.

263 erial engraftment in nonobese diabetic (NOD)/severe combined immunodeficient (SCID) mice.

264 ll as metastatic tumor growth in the lung of severe combined immunodeficient (SCID) mice.

265 mor activity against human MM cell growth in severe combined immunodeficient (SCID) mice.

266 administered intravenously to glioma-bearing severe combined immunodeficient (SCID) mice.

267 scaffolds and implanted subcutaneously into severe combined immunodeficient (SCID) mice.

268 rigel, in coculture with fibroblasts, and in severe combined immunodeficient (SCID) mice.

269 ublethally irradiated nonobese diabetic (NOD)severe combined immunodeficient (SCID) mice.

270 and their splenocytes were transferred into severe combined immunodeficient (SCID) mice.

271 The sLLO strain was cleared by severe combined immunodeficient (SCID) mice.

272 In a severe combined immunodeficient (SCID) mouse model of di

273 Using a severe combined immunodeficient (SCID) mouse model of HI

274 e studied hippocampal synaptic function in a severe combined immunodeficient (SCID) mouse model of HI

275 and tumor formation in an immunocompromized severe combined immunodeficient (SCID) mouse model of or

276 Using a severe combined immunodeficient (SCID) mouse model, we d

277 human renal cell carcinoma in an orthotopic severe combined immunodeficient (SCID) mouse model.

278 ntaneous metastasis assay was performed in a severe combined immunodeficient (SCID) mouse model.

279 med by human prostate cancer cell lines in a severe combined immunodeficient (SCID) mouse tibial inje

280 anti-proliferative effects in the human skin-severe combined immunodeficient (SCID) mouse transplant

281 e show that LRP-1 is abundantly expressed in severe combined immunodeficient (SCID) mouse xenografts

282 in psoriasis in an in vivo system using the severe combined immunodeficient (SCID) mouse-human skin

283 Here, using the severe combined immunodeficient (SCID) mouse-psoriasis x

284 RAG1-mutants from severe combined immunodeficient (SCID) patient cells sho

285 ive to adult bone marrow in allogeneic fetal severe combined immunodeficient (SCID) recipients compar

286 fer of CD8 cells from CD4 knockout mice into severe combined immunodeficient (SCID) recipients.

287 ymphocytes and within human thymic grafts in severe combined immunodeficient (SCID)-hu (Thy/Liv) mice

288 tivities of docetaxel both in culture and in severe combined immunodeficient (SCID)-human model of ex

289 we measure the activity of multipotent human severe combined immunodeficient (SCID)-repopulating cell

290 th pleiotrophin also substantially increased severe combined immunodeficient (SCID)-repopulating cell

291 wn in the epithelium-free mammary fat pad of severe combined immunodeficient (SCID)/Beige and nonobes

292 and after transplantation into the livers of severe combined immunodeficient (SCID)/beige mice.

293 g plasmablasts can be enriched in vivo, in a severe combined immunodeficient (SCID)/beige mouse host.

294 (+) PMF CD34(+) cells into nonobese diabetic/severe combined immunodeficient (SCID)/IL-2Rgamma(null)

295 In the human severe combined immunodeficient (SCID-hu) bone model of

296 ed the growth of primary tumors in the human severe combined immunodeficient (SCID-hu) model of myelo

297 ibodies on an ATL model in nonobese diabetic/severe combined immunodeficient (SCID/NOD) wild-type mic

298 (PMNs) and in human intestinal xenografts in severe-combined immunodeficient (SCID-HU-INT) mice, a no

299 um antibodies to the systemic compartment of severe-combined-immunodeficient (SCID) mice temporarily

300 C57BL/6J or C57BL/6-Prkdc(scid) (severe combined immunodeficient [SCID]) mice were inocul